Literature DB >> 9003762

Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme.

A Friebe1, G Schultz, D Koesling.   

Abstract

It took at least a decade to realize that the toxic gas NO is the physiological activator of soluble guanylyl cyclase (sGC), thereby acting as a signaling molecule in the nervous and cardiovascular systems. Despite its rather poor sGC-activating property, CO has also been implicated as a physiological stimulator of sGC in neurotransmission and vasorelaxation. Here, we establish YC-1 as a novel NO-independent sGC activator that potentiates both CO- and NO-induced sGC stimulation. As this potentiating effect is also observed with protoporphyrin IX which activates sGC independently of a gaseous ligand, we conclude that stabilization of the enzyme's active configuration is the underlying mechanism of YC-1's action. Moreover, the results obtained with YC-1 reveal that CO is capable of stimulating sGC to a degree similar to NO, and thus provide the molecular basis for CO functioning as a signaling molecule.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9003762      PMCID: PMC452512     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  45 in total

1.  Positive effects of pollution.

Authors:  A Friebe; J Malkewitz; G Schultz; D Koesling
Journal:  Nature       Date:  1996-07-11       Impact factor: 49.962

2.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

Authors:  W P Arnold; C K Mittal; S Katsuki; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

Review 3.  Regulation of purified soluble guanylate cyclase by porphyrins and metalloporphyrins: a unifying concept.

Authors:  L J Ignarro; K S Wood; M S Wolin
Journal:  Adv Cyclic Nucleotide Protein Phosphorylation Res       Date:  1984

4.  Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung.

Authors:  L J Ignarro; J N Degnan; W H Baricos; P J Kadowitz; M S Wolin
Journal:  Biochim Biophys Acta       Date:  1982-09-17

5.  Activation of purified soluble guanylate cyclase by protoporphyrin IX.

Authors:  L J Ignarro; K S Wood; M S Wolin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

6.  A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits.

Authors:  J Foerster; C Harteneck; J Malkewitz; G Schultz; D Koesling
Journal:  Eur J Biochem       Date:  1996-09-01

7.  [Studies on heterocyclic compounds. XXXIV. Synthesis of furo[3,2-c]pyrazole derivatives. (2). Electrophilic substitution of 1,3-diphenylfuro[3,2-c]pyrazole (author's transl)].

Authors:  S Yoshina; A Tanaka; S C Kuo
Journal:  Yakugaku Zasshi       Date:  1978-02       Impact factor: 0.302

8.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

9.  Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase.

Authors:  B Brüne; V Ullrich
Journal:  Mol Pharmacol       Date:  1987-10       Impact factor: 4.436

10.  Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms.

Authors:  L J Ignarro; J B Adams; P M Horwitz; K S Wood
Journal:  J Biol Chem       Date:  1986-04-15       Impact factor: 5.157

View more
  80 in total

1.  YC-1 potentiates nitric oxide-induced relaxation in guinea-pig trachea.

Authors:  T L Hwang; C C Wu; C M Teng
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 2.  Isoforms of NO-sensitive guanylyl cyclase.

Authors:  Michael Russwurm; Doris Koesling
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

3.  Attenuated response of L-type calcium current to nitric oxide in atrial fibrillation.

Authors:  Nadiia Rozmaritsa; Torsten Christ; David R Van Wagoner; Hannelore Haase; Johannes-Peter Stasch; Klaus Matschke; Ursula Ravens
Journal:  Cardiovasc Res       Date:  2013-12-12       Impact factor: 10.787

Review 4.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 5.  Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Authors:  David A Tulis
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

6.  YC-1 binding to the β subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the α subunit.

Authors:  Rahul Purohit; Bradley G Fritz; Juliana The; Aaron Issaian; Andrzej Weichsel; Cynthia L David; Eric Campbell; Andrew C Hausrath; Leida Rassouli-Taylor; Elsa D Garcin; Matthew J Gage; William R Montfort
Journal:  Biochemistry       Date:  2013-12-30       Impact factor: 3.162

Review 7.  Carbon monoxide--physiology, detection and controlled release.

Authors:  Stefan H Heinemann; Toshinori Hoshi; Matthias Westerhausen; Alexander Schiller
Journal:  Chem Commun (Camb)       Date:  2014-04-11       Impact factor: 6.222

8.  A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase.

Authors:  Nathaniel B Fernhoff; Emily R Derbyshire; Michael A Marletta
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

9.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013

10.  Stimulation of soluble guanylate cyclase by superoxide dismutase is mediated by NO.

Authors:  A Friebe; G Schultz; D Koesling
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.